摘要
药源性肝损伤是临床常见的药物不良反应之一,且时至今日仍然是药物限制使用、研发终止和上市后警告撤市的主要原因。近年来,中药中多种化学成分及代谢产物和二者通过代谢影响的内源性效应物质因具有良好的保肝活性备受关注,但目前中药抗药源性肝损伤的机制复杂、效应物质尚不明确,且其与代谢相关的研究仍比较薄弱。因此本文从代谢的角度对药源性肝损伤的机制以及其中药治疗的机制进行综述,并首次创新性地将中药效应物质分为外源性(中药活性成分及代谢物)和内源性(肠道益生菌、内源性代谢产物)两大类,为减少药源性肝损伤发生,探索并开发有效的中药抗药源性肝损伤效应物质,并进一步研制具有肝保护作用的临床药物提供参考。
Drug-induced liver injury(DILI)is one of the common clinical adverse drug reactions and remains a major cause of drug restriction,development termination and withdrawal from the pharmaceutical market today.In recent years,a variety of chemical components and metabolites of traditional Chinese medicine(TCM),as well as the endogenous effector substances influenced by metabolism of both,have attracted much attention for their significant hepatoprotective activities.However,the mechanism of TCM against DILI is complex,the related effector substances are still unclear,and its metabolism-related studies are still relatively weak.Therefore,this review summarized the mechanisms of DILI and its treatment by TCM from the perspective of metabolism,and for the first time,innovatively classified the Chinese medicine effector substances into two categories:exogenous(active components and metabolites of TCM)and endogenous(intestinal probiotics and endogenous metabolites),in order to reduce the occurrence of DILI,explore and develop effective anti-drug-induced liver injury effector substances of TCM,and further develop clinical drugs with hepatoprotective effects.
作者
黄心慧
周婷婷
HUANG Xin-hui;ZHOU Ting-ting(School of Pharmacy,Navy Military Medical University,Shanghai 200433,China;Shanghai Key Laboratory for Pharmaceutical(Chinese Materia Medica)Metabolite Research,Shanghai 200433,China)
出处
《药学学报》
CAS
CSCD
北大核心
2023年第3期646-658,共13页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81973457)。
关键词
药源性肝损伤
中药治疗
作用机制
效应物质
代谢
drug-induced liver injury
treatment by traditional Chinese medicine
mechanism
effector substance
metabolism
